ReviewClinical and experimental medicine2026
Non-TNF-targeted drugs in rheumatic diseasescombined with latent tuberculosis infection.
Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic diseases(RD), a collection of autoimmune disorders affecting connective tissues, have a global prevalence of approximately 3%-5%. Characterized by immune-mediated attacks on the body's own tissues, these conditions lead to inflammation and tissue damage. Rheumatic disease patients frequently receive glucocorticoids, immunosuppressants, and biological agents, potentially elevating the risk of latent tuberculosis infection (LTBI) reactivation and Mycobacterium Tuberculosis (MTB) dissemination. Tumor necrosis factor-α(TNF-α)is crucial in immune responses, and TNF-targeted therapies could raise the risk of advancing from LTBI to active tuberculosis(TB). Compared to TNF inhibitors, non-TNF-targeted drugs-including IL-6, JAK, and B-cell inhibitors-pose a lower TB reactivation risk but may still modulate immune responses and defense against MTB. Our review synthesizes clinical research advancements in non-TNF-targeted therapies for rheumatic diseases, focusing on their association with TB reactivation risk. Non-TNF-targeted therapies demonstrate a reduced TB reactivation risk in rheumatic disease treatment, yet they necessitate rigorous TB screening and surveillance. Comprehensive infection status evaluation and prophylactic anti-tuberculosis treatment are essential for LTBI patients prior to therapy. The risk of TB infection is heightened in rheumatic disease patients undergoing biological therapy, particularly with TNF inhibitors. Despite the lower risk with non-TNF-targeted therapies, stringent screening and ongoing monitoring are imperative. Clinical practice should involve thorough patient assessment, personalized treatment planning, and preventive anti-tuberculosis strategies to balance therapeutic efficacy and infection risk. Further studies are warranted to elucidate the link between non-TNF-targeted therapies and TB risk and to refine treatment strategies for rheumatic diseases.This review seeks to investigate the potential TB reactivation risk associated with non-TNF-targeted therapies in rheumatic diseases and to offer theoretical foundations and novel perspectives for their clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.